Skip to main content
. 2017 Jul 14;8:16085. doi: 10.1038/ncomms16085

Figure 6. Vaccination with MTBVAC induces a CFP10-specific immune response in humans.

Figure 6

Specific IFNγ ELISPOT results from the first-in-human MTBVAC clinical trial are shown for CFP10 (a,b) and ESAT6 (c,d), comparing for each volunteer the number of spots pre- and post-BCG (b,d) and MTBVAC (a,c) vaccination with 5 × 105 CFU. Wilcoxon matched-pairs signed rank test was used to compare pre- and post-vaccination status for each vaccine and antigen. P value is indicated for MTBVAC vaccinees.